Sigma-Aldrich has agreed to acquire BioReliance from Avista Capital Partners for $350 million in cash. The acquisition is subject to customary closing conditions, including regulatory clearance, and is expected to close in the first quarter of 2012. BioReliance provides biologics testing, specialized toxicology and animal health testing worldwide. BioReliance generated revenues of approximately $110 million in 2010 was projected to have double-digit growth expected in 2011. Avista Capital Partn...